Sutro Biopharma, Inc. (STRO) compared with its closest peers (CMPX, LXEO, XFOR, IPSC, PALI). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | $431.31M | -12.8 |
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $399.98M | -5.3 |
| X4 Pharmaceuticals, Inc. (XFOR) | $380.11M | -2.1 |
| Century Therapeutics, Inc. (IPSC) | $373.92M | -7.0 |
| Palisade Bio, Inc. (PALI) | $367.71M | -7.9 |
| Agenus Inc. (AGEN) | $336.68M | 2.4 |
| Inhibikase Therapeutics, Inc. (IKT) | $333.49M | -4.2 |
| Neumora Therapeutics, Inc. Common Stock (NMRA) | $304.39M | -1.2 |
| Anavex Life Sciences Corp. (AVXL) | $296.55M | -16.5 |
| Fate Therapeutics, Inc. (FATE) | $277.98M | -0.9 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
STRO overview · STRO earnings · STRO financials · STRO KPIs · STRO investor relations · STRO ownership · STRO filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.